Tags

Type your tag names separated by a space and hit enter

Long-term supplementation with alpha-tocopherol and beta-carotene and age-related cataract.

Abstract

PURPOSE

To study if long-term supplementation with alpha-tocopherol or beta-carotene is associated with cataract prevalence and severity.

METHODS

An end-of-trial random sample of 1828 participants from the randomized, double-blind, placebo-controlled clinical trial the alpha-tocopherol, beta-carotene cancer prevention study. The alpha-tocopherol, beta-carotene cancer prevention study was originally designed to examine whether supplementation with alpha-tocopherol or beta-carotene would reduce the incidence of lung cancer in male smokers. The participants for this study lived in Helsinki City or Uusimaa province and were at entry to the alpha-tocopherol, beta-carotene cancer prevention study 50 to 69 years old and smoked at least 5 cigarettes per day. They received alpha-tocopherol 50 mg/day, beta-carotene 20 mg/day, a combination of the two, or placebo supplements for 5 to 8 years (median 6.6 years). Outcome measures were: cortical, nuclear, and posterior subcapsular cataract, differentiated and quantified with lens opacity classification system (LOCS II). Lens opacity meter provided a continuous measure of cataract density.

RESULTS

Supplementation with alpha-tocopherol or beta-carotene was not associated with the end-of-trial prevalence of nuclear (odds ratio 1.1 and 1.2, respectively), cortical (odds ratio 1.0 and 1.3, respectively), or posterior subcapsular cataract (odds ratio 1.1 and 1.0, respectively) when adjusted for possible confounders in logistic model. Neither did the median lens opacity meter values differ between the supplementation groups, indicating no effect of alpha-tocopherol or beta-carotene on cataract severity.

CONCLUSION

Supplementation with alpha-tocopherol or beta-carotene for 5 to 8 years does not influence the cataract prevalence among middle-aged, smoking men.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    University of Helsinki, Finland. teikari@pp.kolumbus.fi

    , , , ,

    Source

    Acta ophthalmologica Scandinavica 75:6 1997 Dec pg 634-40

    MeSH

    Aged
    Aging
    Antioxidants
    Cataract
    Double-Blind Method
    Drug Therapy, Combination
    Finland
    Follow-Up Studies
    Humans
    Lens, Crystalline
    Lung Neoplasms
    Male
    Middle Aged
    Prevalence
    Risk Factors
    Vitamin E
    beta Carotene

    Pub Type(s)

    Clinical Trial
    Comparative Study
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    9527321

    Citation

    Teikari, J M., et al. "Long-term Supplementation With Alpha-tocopherol and Beta-carotene and Age-related Cataract." Acta Ophthalmologica Scandinavica, vol. 75, no. 6, 1997, pp. 634-40.
    Teikari JM, Virtamo J, Rautalahti M, et al. Long-term supplementation with alpha-tocopherol and beta-carotene and age-related cataract. Acta Ophthalmol Scand. 1997;75(6):634-40.
    Teikari, J. M., Virtamo, J., Rautalahti, M., Palmgren, J., Liesto, K., & Heinonen, O. P. (1997). Long-term supplementation with alpha-tocopherol and beta-carotene and age-related cataract. Acta Ophthalmologica Scandinavica, 75(6), pp. 634-40.
    Teikari JM, et al. Long-term Supplementation With Alpha-tocopherol and Beta-carotene and Age-related Cataract. Acta Ophthalmol Scand. 1997;75(6):634-40. PubMed PMID: 9527321.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Long-term supplementation with alpha-tocopherol and beta-carotene and age-related cataract. AU - Teikari,J M, AU - Virtamo,J, AU - Rautalahti,M, AU - Palmgren,J, AU - Liesto,K, AU - Heinonen,O P, PY - 1998/4/4/pubmed PY - 1998/4/4/medline PY - 1998/4/4/entrez SP - 634 EP - 40 JF - Acta ophthalmologica Scandinavica JO - Acta Ophthalmol Scand VL - 75 IS - 6 N2 - PURPOSE: To study if long-term supplementation with alpha-tocopherol or beta-carotene is associated with cataract prevalence and severity. METHODS: An end-of-trial random sample of 1828 participants from the randomized, double-blind, placebo-controlled clinical trial the alpha-tocopherol, beta-carotene cancer prevention study. The alpha-tocopherol, beta-carotene cancer prevention study was originally designed to examine whether supplementation with alpha-tocopherol or beta-carotene would reduce the incidence of lung cancer in male smokers. The participants for this study lived in Helsinki City or Uusimaa province and were at entry to the alpha-tocopherol, beta-carotene cancer prevention study 50 to 69 years old and smoked at least 5 cigarettes per day. They received alpha-tocopherol 50 mg/day, beta-carotene 20 mg/day, a combination of the two, or placebo supplements for 5 to 8 years (median 6.6 years). Outcome measures were: cortical, nuclear, and posterior subcapsular cataract, differentiated and quantified with lens opacity classification system (LOCS II). Lens opacity meter provided a continuous measure of cataract density. RESULTS: Supplementation with alpha-tocopherol or beta-carotene was not associated with the end-of-trial prevalence of nuclear (odds ratio 1.1 and 1.2, respectively), cortical (odds ratio 1.0 and 1.3, respectively), or posterior subcapsular cataract (odds ratio 1.1 and 1.0, respectively) when adjusted for possible confounders in logistic model. Neither did the median lens opacity meter values differ between the supplementation groups, indicating no effect of alpha-tocopherol or beta-carotene on cataract severity. CONCLUSION: Supplementation with alpha-tocopherol or beta-carotene for 5 to 8 years does not influence the cataract prevalence among middle-aged, smoking men. SN - 1395-3907 UR - https://www.unboundmedicine.com/medline/citation/9527321/Long_term_supplementation_with_alpha_tocopherol_and_beta_carotene_and_age_related_cataract_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1395-3907&date=1997&volume=75&issue=6&spage=634 DB - PRIME DP - Unbound Medicine ER -